R. Lee, P. Saylor, and M. Smith, Treatment and prevention of bone complications from prostate cancer, Bone, vol.48, issue.1, pp.88-95, 2011.
DOI : 10.1016/j.bone.2010.05.038

V. Butoescu and B. Tombal, Practical guide to bone health in the spectrum of advanced prostate cancer, Can J Urol. 2014, vol.21, issue.2, pp.84-92

P. Saylor, Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer, Asian Journal of Andrology, vol.16, issue.3, p.341, 2014.
DOI : 10.4103/1008-682X.122591

R. Coleman, Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity. Clin Cancer Res, pp.6243-6249, 2006.

C. Parker, S. Nilsson, D. Heinrich, S. Helle, O. Sullivan et al., Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013.
DOI : 10.1056/NEJMoa1213755

J. Bruder, J. Ma, J. Basler, and M. Welch, Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy, Urology, vol.67, issue.1, pp.152-157, 2006.
DOI : 10.1016/j.urology.2005.07.017

K. Weinfurt, The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer, Annals of Oncology, vol.16, issue.4, pp.579-84, 2005.
DOI : 10.1093/annonc/mdi122

V. Depuy, K. Anstrom, L. Castel, K. Schulman, K. Weinfurt et al., Effects of skeletal morbidities on longitudinal patient-­?reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer, pp.869-76, 2007.

M. Broder, B. Gutierrez, D. Cherepanov, and Y. Linhares, Burden of skeletal-­?related events in prostate cancer: unmet need in pain improvement. Support Care Cancer, pp.237-284, 2015.

D. Amelio, P. Isaia, and G. , Male Osteoporosis in the Elderly, Int J Endocrinol, vol.2015, pp.1-8, 2015.

O. Johnell and J. Kanis, An estimate of the worldwide prevalence and disability associated with osteoporotic fractures, Osteoporosis International, vol.16, issue.suppl 2, pp.1726-1759, 2006.
DOI : 10.1007/s00198-006-0172-4

C. Wang and Y. Shen, Study on the distribution features of bone metastases in prostate cancer, Nuclear Medicine Communications, vol.33, issue.4
DOI : 10.1097/MNM.0b013e3283504528

D. Mittan, S. Lee, E. Miller, R. Perez, J. Basler et al., Bone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs, The Journal of Clinical Endocrinology & Metabolism, vol.87, issue.8, pp.3656-61, 2002.
DOI : 10.1210/jcem.87.8.8782

J. Kanis, H. Johansson, A. Oden, O. Johnell, C. De-laet et al., A Meta-Analysis of Prior Corticosteroid Use and Fracture Risk, Journal of Bone and Mineral Research, vol.359, issue.6, pp.893-902, 2004.
DOI : 10.1359/JBMR.040134

T. Dorff and E. Crawford, Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer, Annals of Oncology, vol.24, issue.1, pp.31-39, 2013.
DOI : 10.1093/annonc/mds216

A. Aparicio, A. Harzstark, P. Corn, S. Wen, J. Araujo et al., Platinum-­?Based Chemotherapy for Variant Castrate-­?Resistant Prostate Cancer. Clin Cancer Res, pp.3621-3651, 2013.
DOI : 10.1158/1078-0432.ccr-12-3791

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699964

A. Gangi, T. Sabharwal, F. Irani, X. Buy, J. Morales et al., Quality Assurance Guidelines for Percutaneous Vertebroplasty, CardioVascular and Interventional Radiology, vol.18, issue.1, pp.173-181, 2006.
DOI : 10.1007/s00270-005-0146-5

J. Laredo, K. Lakhdari, L. Bellaïche, B. Hamze, P. Janklewicz et al., Acute vertebral collapse: CT findings in benign and malignant nontraumatic cases., Radiology, vol.194, issue.1, pp.41-49, 1995.
DOI : 10.1148/radiology.194.1.7997579

C. Cuénod, J. Laredo, S. Chevret, B. Hamze, J. Naouri et al., Acute vertebral collapse due to osteoporosis or malignancy: appearance on unenhanced and gadolinium-enhanced MR images., Radiology, vol.199, issue.2, pp.541-550, 1996.
DOI : 10.1148/radiology.199.2.8668809

W. Yuh, C. Zachar, T. Barloon, Y. Sato, W. Sickels et al., Vertebral compression fractures: distinction between benign and malignant causes with MR imaging., Radiology, vol.172, issue.1, 1989.
DOI : 10.1148/radiology.172.1.2740506

T. Van-staa, H. Leufkens, L. Abenhaim, B. Zhang, and C. Cooper, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, Rheumatology, vol.39, issue.12, pp.215-223, 2000.
DOI : 10.1093/rheumatology/39.12.1383

R. Coleman, J. Body, M. Aapro, P. Hadji, and J. Herrstedt, Bone health in cancer patients: ESMO Clinical Practice Guidelines, Annals of Oncology, vol.25, issue.suppl 3, pp.124-161, 2014.
DOI : 10.1093/annonc/mdu103

V. Shahinian, Y. Kuo, J. Freeman, and J. Goodwin, Risk of Fracture after Androgen Deprivation for Prostate Cancer, New England Journal of Medicine, vol.352, issue.2, pp.154-64, 2005.
DOI : 10.1056/NEJMoa041943

S. Alibhai, M. Duong-­?hua, A. Cheung, R. Sutradhar, P. Warde et al., Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men, The Journal of Urology, vol.184, issue.3, pp.918-941, 2010.
DOI : 10.1016/j.juro.2010.04.068

M. Smith, Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.31, pp.7897-903, 2005.
DOI : 10.1200/JCO.2004.00.6908

. Chaumard-­?billotey, Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC), ASCO Annu Meet, 2013.

P. Ferrari, Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease, Best Practice & Research Clinical Endocrinology & Metabolism, vol.17, issue.4, pp.575-89, 2003.
DOI : 10.1016/S1521-690X(03)00053-8

R. Coleman, E. Rathbone, and J. Brown, Management of cancer treatment-induced bone loss, Nature Reviews Rheumatology, vol.22, issue.6
DOI : 10.1038/nrrheum.2013.36

J. Morote, J. Morin, A. Orsola, J. Abascal, C. Salvador et al., Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer, Urology, vol.69, issue.3, pp.500-504, 2007.
DOI : 10.1016/j.urology.2006.11.002

D. Berthold, G. Pond, F. Soban, R. De-wit, M. Eisenberger et al., Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study, Journal of Clinical Oncology, vol.26, issue.2, pp.242-247, 2008.
DOI : 10.1200/JCO.2007.12.4008

D. Bono and J. , Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-­?resistant prostate cancer progressing after docetaxel treatment: a randomised open-­?label trial, Lancet, 2010.

D. Bono, J. Logothetis, C. Molina, A. , K. Fizazi et al., Abiraterone and Increased Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.364, issue.21, pp.1995-2005, 2011.
DOI : 10.1056/NEJMoa1014618

C. Ryan, M. Smith, K. Fizazi, F. Saad, P. Mulders et al., Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, The Lancet Oncology, vol.16, issue.2, pp.152-60, 2015.
DOI : 10.1016/S1470-2045(14)71205-7

K. Fizazi, K. Chi, J. De-bono, L. Gomella, K. Miller et al., Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer, European Urology, vol.70, issue.3, 2016.
DOI : 10.1016/j.eururo.2016.02.035

F. Saad, D. Gleason, R. Murray, S. Tchekmedyian, P. Venner et al., Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer, JNCI Journal of the National Cancer Institute, vol.96, issue.11, pp.879-82, 2004.
DOI : 10.1093/jnci/djh141

K. Fizazi, M. Carducci, M. Smith, R. Damião, J. Brown et al., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-­?resistant prostate cancer: a randomised, double-­?blind study. The Lancet Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-­?Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance), EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-­?Resistant Prostate Cancer, pp.813-835, 2011.

M. Datta and G. Schwartz, Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review, The Oncologist, vol.17, issue.9, pp.1171-1180, 2012.
DOI : 10.1634/theoncologist.2012-0051

R. Govindarajan, M. Khan, S. Gujja, A. Holt, H. Breunis et al., Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy, Management of decreased bone mineral density in men starting androgen-­?deprivation therapy for prostate cancer
DOI : 10.2147/CMAR.S74116

S. Schuit, M. Van-der-klift, A. Weel, C. De-laet, H. Burger et al., Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study, Bone, vol.34, issue.1, pp.195-202, 2004.
DOI : 10.1016/j.bone.2003.10.001

J. Kanis, O. Johnell, A. Oden, H. Johansson, and E. Mccloskey, FRAX TM and the assessment of fracture probability in men and women from the UK. Osteoporos Int, pp.385-97, 2008.

R. Weston, A. Hussain, E. George, and N. Parr, Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer, BJU International, vol.133, issue.6, pp.776-785, 2005.
DOI : 10.1016/S0090-4295(99)00061-8

P. Sargos, N. Mamou, C. Dejean, B. Figueiredo, . De et al., Dose de tolérance à l'irradiation des tissus sains : l'os chez l'adulte. Cancer/Radiothérapie, pp.386-91, 2010.

C. Higham and S. Faithfull, Bone Health and Pelvic Radiotherapy, Clinical Oncology, vol.27, issue.11, p.2015
DOI : 10.1016/j.clon.2015.07.006

K. Pilz, A. Hoffmann, M. Baumann, and E. Troost, Vertebral fractures ??? An underestimated side-effect in patients treated with radio(chemo)therapy, Radiotherapy and Oncology, vol.118, issue.3, 2016.
DOI : 10.1016/j.radonc.2016.02.021

P. Tai, A. Hammond, J. Dyk, L. Stitt, T. J. Coad et al., Pelvic fractures following irradiation of endometrial and vaginal cancers???a case series and review of literature, Radiotherapy and Oncology, vol.56, issue.1, pp.23-31, 2000.
DOI : 10.1016/S0167-8140(00)00178-X

G. Michel, P. Blery, P. Pilet, J. Guicheux, P. Weiss et al., Micro-CT Analysis of Radiation-Induced Osteopenia and Bone Hypovascularization in Rat, Calcified Tissue International, vol.170, issue.3, 2015.
DOI : 10.1007/s00223-015-0010-9

S. Hamilton, M. Pecaut, D. Gridley, N. Travis, E. Bandstra et al., A murine model for bone loss from therapeutic and space-relevant sources of radiation, Journal of Applied Physiology, vol.101, issue.3, pp.789-93, 1985.
DOI : 10.1152/japplphysiol.01078.2005

S. I?dem, G. Alço, T. Ercan, M. Barlan, K. Ganiyusufo?lu et al., Insufficiency Fractures After Pelvic Radiotherapy in Patients With Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.77, issue.3, pp.818-841, 2010.
DOI : 10.1016/j.ijrobp.2009.05.059

H. Beltran, S. Tomlins, A. Aparicio, V. Arora, D. Rickman et al., Aggressive Variants of Castration-­?Resistant Prostate Cancer. Clin Cancer Res, pp.2846-50, 2014.

X. Rébillard, P. Grosclaude, N. Leone, M. Velten, G. Coureau et al., Projection de l???incidence et de la mortalit?? par cancer urologique en France en 2012, VI. BIBLIOGRAPHIE 1. International Agency for Research on Cancer. GLOBOACAN 2012, pp.57-65, 2013.
DOI : 10.1016/S1166-7087(13)70047-2

M. Soulié, P. Coloby, J. Irani, T. Lebret, J. Patard et al., Diagnosis, treatment, follow up of urological cancers], CCAFU Recommendations Prog En Urol J Assoc Fr Urol Société Fr Urol, vol.2013, 2013.

M. Auprich, H. Augustin, L. Budäus, L. Kluth, S. Mannweiler et al., A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy, BJU International, vol.349, issue.11, pp.1627-1662, 2012.
DOI : 10.1111/j.1464-410X.2011.10584.x

F. Schröder, J. Hugosson, S. Carlsson, T. Tammela, L. Määttänen et al., Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC), European Urology, vol.62, issue.5, pp.745-52, 2012.
DOI : 10.1016/j.eururo.2012.05.068

A. Heidenreich, P. Abrahamsson, W. Artibani, J. Catto, F. Montorsi et al., Early Detection of Prostate Cancer: European Association of Urology Recommendation, European Urology, vol.64, issue.3, pp.347-54, 2013.
DOI : 10.1016/j.eururo.2013.06.051

M. Han, A. Partin, C. Pound, J. Epstein, and P. Walsh, Long-­?term biochemical disease-­?free and cancer-­? specific survival following anatomic radical retropubic prostatectomy. The 15-­?year Johns Hopkins experience
DOI : 10.1016/s0094-0143(05)70163-4

C. Pound, A. Partin, M. Eisenberger, D. Chan, J. Pearson et al., Natural History of Progression After PSA Elevation Following Radical Prostatectomy, JAMA, vol.281, issue.17, pp.1591-1598, 1999.
DOI : 10.1001/jama.281.17.1591

J. Epstein, W. Allsbrook, M. Amin, L. Egevad, and . Isup-grading-committee, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma, pp.1228-1270, 2005.
DOI : 10.1097/01.pas.0000173646.99337.b1

A. Briganti, A. Larcher, F. Abdollah, U. Capitanio, A. Gallina et al., Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores, European Urology, vol.61, issue.3, pp.480-487, 2012.
DOI : 10.1016/j.eururo.2011.10.044

P. Harnden, M. Shelley, H. Clements, B. Coles, R. Tyndale-­?biscoe et al., The prognostic significance of perineural invasion in prostatic cancer biopsies, Cancer, vol.97, issue.1, pp.13-24, 2007.
DOI : 10.1002/cncr.22388

O. Yossepowitch, A. Bjartell, J. Eastham, M. Graefen, B. Guillonneau et al., Positive Surgical Margins in Radical Prostatectomy: Outlining the Problem and Its Long-Term Consequences, European Urology, vol.55, issue.1, pp.87-99, 2009.
DOI : 10.1016/j.eururo.2008.09.051

H. Vargas, O. Akin, T. Franiel, Y. Mazaheri, J. Zheng et al., Diffusion-weighted Endorectal MR Imaging at 3 T for Prostate Cancer: Tumor Detection and Assessment of Aggressiveness, Radiology, vol.259, issue.3, pp.775-84, 2011.
DOI : 10.1148/radiol.11102066

S. Edge and C. Compton, The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM, Annals of Surgical Oncology, vol.17, issue.6, pp.1471-1475, 2010.
DOI : 10.1245/s10434-010-0985-4

D. Amico, A. Whittington, R. Malkowicz, S. Schultz, D. Blank et al., Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer, JAMA, vol.280, issue.11, pp.969-74, 1998.
DOI : 10.1001/jama.280.11.969

J. Epstein, L. Egevad, M. Amin, B. Delahunt, J. Srigley et al., Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System V, on behalf of the ESMO Guidelines Working Group Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-­?up, International Society of Urological Pathology Am J Surg Pathol. Feb Ann Oncol, vol.4024, issue.2 6, pp.244-52, 2013.

M. Umbehr, M. Müntener, T. Hany, T. Sulser, and L. Bachmann, The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis, European Urology, vol.64, issue.1, pp.106-123
DOI : 10.1016/j.eururo.2013.04.019

I. Brenot-­?rossi, Mise au point??: TEP-choline et cancer de la prostate, Progr??s en Urologie, vol.24, issue.1, pp.3-8
DOI : 10.1016/j.purol.2013.07.016

C. Huggins and C. Hodges, Studies on prostatic cancer, Cancer Res, vol.1, p.297, 1941.

Y. Kim, S. Alarcon, S. Lee, M. Lee, G. Giaccone et al., Update on Hsp90 Inhibitors in Clinical Trial, Current Topics in Medicinal Chemistry, vol.9, issue.15, pp.1479-92, 2009.
DOI : 10.2174/156802609789895728

I. Hughes, J. Davies, T. Bunch, V. Pasterski, K. Mastroyannopoulou et al., Androgen insensitivity syndrome. The Lancet, pp.1419-1447, 2012.

A. Shafi, A. Yen, and N. Weigel, Androgen receptors in hormone-dependent and castration-resistant prostate cancer, Pharmacology & Therapeutics, vol.140, issue.3, pp.223-261, 2013.
DOI : 10.1016/j.pharmthera.2013.07.003

E. Gelmann, Molecular Biology of the Androgen Receptor, Journal of Clinical Oncology, vol.20, issue.13, pp.3001-3016, 2002.
DOI : 10.1200/JCO.2002.10.018

T. Chandrasekar, J. Yang, A. Gao, and C. Evans, Mechanisms of resistance in castration-­?resistant prostate cancer (CRPC), Transl Androl Urol, vol.4, issue.3, pp.365-80, 2015.

B. Feldman and D. Feldman, The development of androgen-independent prostate cancer, Nature Reviews Cancer, vol.1, issue.1, pp.34-45, 2001.
DOI : 10.1038/35094009

J. Yu, J. Yu, R. Mani, Q. Cao, C. Brenner et al., An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-­?ERG Gene Fusions in Prostate Cancer Progression. Cancer Cell, pp.443-54, 2010.

J. Zarif and C. Miranti, The importance of non-­?nuclear AR signaling in prostate cancer progression and therapeutic resistance. Cell Signal, pp.348-56, 2016.

E. Antonarakis, C. Lu, H. Wang, B. Luber, M. Nakazawa et al., AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer, New England Journal of Medicine, vol.371, issue.11, pp.1028-1066, 2014.
DOI : 10.1056/NEJMoa1315815

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4201502

R. Hu, T. Dunn, S. Wei, S. Isharwal, R. Veltri et al., Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer, Cancer Research, vol.69, issue.1, pp.16-22, 2009.
DOI : 10.1158/0008-5472.CAN-08-2764

P. Toren, S. Kim, S. Pham, A. Mangalji, H. Adomat et al., Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer, Molecular Cancer Therapeutics, vol.14, issue.1, pp.59-69, 2015.
DOI : 10.1158/1535-7163.MCT-14-0521

C. Bastide, F. Bruyère, G. Karsenty, L. Guy, and F. Rozet, Le traitement hormonal du cancer de la prostate, Progr??s en Urologie, vol.23, issue.15, pp.1246-57, 2013.
DOI : 10.1016/j.purol.2013.08.325

Y. Xu, Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers. Clin Cancer Res, pp.4072-4081, 2006.

G. Kolvenbag, B. Furr, and G. Blackledge, Receptor affinity and potency of non-­?steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis, 1998.

C. Tran, S. Ouk, N. Clegg, Y. Chen, P. Watson et al., Development of a Second-­?Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science, pp.787-90, 2009.

W. Harris, E. Mostaghel, P. Nelson, and B. Montgomery, Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion, Nat Clin Pract Urol, 2009.

H. Scher, S. Halabi, I. Tannock, M. Morris, C. Sternberg et al., Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, Journal of Clinical Oncology, vol.26, issue.7, pp.1148-59, 2008.
DOI : 10.1200/JCO.2007.12.4487

C. Chen, D. Welsbie, C. Tran, S. Baek, R. Chen et al., Molecular determinants of resistance to antiandrogen therapy, Nature Medicine, vol.10, issue.1, pp.33-42, 2004.
DOI : 10.1038/nm972

H. Heemers and D. Tindall, Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex, Endocrine Reviews, vol.28, issue.7, pp.778-808, 2007.
DOI : 10.1210/er.2007-0019

T. Wilt, M. Brawer, K. Jones, M. Barry, W. Aronson et al., Radical Prostatectomy versus Observation for Localized Prostate Cancer Radical prostatectomy versus watchful waiting in early prostate cancer, N Engl J Med N Engl J Med, vol.367364, issue.4318, pp.203-131708, 2011.

A. Widmark, O. Klepp, A. Solberg, J. Damber, A. Angelsen et al., Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial, The Lancet, vol.373, issue.9660, pp.301-309, 2009.
DOI : 10.1016/S0140-6736(08)61815-2

P. Warde, M. Mason, K. Ding, P. Kirkbride, M. Brundage et al., Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial, The Lancet, vol.378, issue.9809, pp.2104-2115, 2012.
DOI : 10.1016/S0140-6736(11)61095-7

E. Horwitz, K. Bae, G. Hanks, A. Porter, D. Grignon et al., Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer, Journal of Clinical Oncology, vol.26, issue.15, pp.2497-504, 2008.
DOI : 10.1200/JCO.2007.14.9021

M. Bolla, D. Reijke, T. Van-tienhoven, G. Van-den-bergh, A. Oddens et al., Duration of Androgen Suppression in the Treatment of Prostate Cancer, New England Journal of Medicine, vol.360, issue.24, pp.2516-2543, 2009.
DOI : 10.1056/NEJMoa0810095

URL : https://hal.archives-ouvertes.fr/hal-00492521

M. Simmons, A. Stephenson, and E. Klein, Natural History of Biochemical Recurrence after Radical Prostatectomy: Risk Assessment for Secondary Therapy, European Urology, vol.51, issue.5, pp.1175-84, 2007.
DOI : 10.1016/j.eururo.2007.01.015

M. Roach, G. Hanks, H. Thames, P. Schellhammer, W. Shipley et al., Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference, International Journal of Radiation Oncology*Biology*Physics, vol.65, issue.4, pp.965-74, 2006.
DOI : 10.1016/j.ijrobp.2006.04.029

A. Stephenson, S. Shariat, M. Zelefsky, M. Kattan, E. Butler et al., Salvage Radiotherapy for Recurrent Prostate Cancer After Radical Prostatectomy, JAMA, vol.291, issue.11, pp.1325-1357, 2004.
DOI : 10.1001/jama.291.11.1325

J. Crook, O. Callaghan, C. Duncan, G. Dearnaley, D. Higano et al., Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group, N Engl J Med Br J Urol Feb, vol.36779, issue.102, pp.895-903, 1997.

A. Kaisary, C. Tyrrell, W. Peeling, and K. Griffiths, Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma, British Journal of Urology, vol.35, issue.5, pp.502-510, 1991.
DOI : 10.1111/j.1464-410X.1991.tb15195.x

N. Vogelzang, G. Chodak, M. Soloway, N. Block, P. Schellhammer et al., Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial, Urology, vol.46, issue.2, pp.220-226, 1995.
DOI : 10.1016/S0090-4295(99)80197-6

J. Seidenfeld, D. Samson, V. Hasselblad, N. Aronson, P. Albertsen et al., Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer, Annals of Internal Medicine, vol.132, issue.7, pp.566-77, 2000.
DOI : 10.7326/0003-4819-132-7-200004040-00009

P. Group, Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials, The Lancet, vol.355, issue.9214, pp.1491-1499, 2000.

M. Hussain, C. Tangen, D. Berry, C. Higano, E. Crawford et al., Intermittent versus Continuous Androgen Deprivation in Prostate Cancer, New England Journal of Medicine, vol.368, issue.14, pp.1314-1339, 2013.
DOI : 10.1056/NEJMoa1212299

C. Sweeney, Y. Chen, M. Carducci, G. Liu, D. Jarrard et al., Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, New England Journal of Medicine, vol.373, issue.8, pp.737-783, 2015.
DOI : 10.1056/NEJMoa1503747

N. James, M. Sydes, N. Clarke, M. Mason, D. Dearnaley et al., Addition of docetaxel, zoledronic acid, or both to first-­?line long-­?term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet Androgen-­?deprivation therapy alone or with docetaxel in non-­?castrate metastatic prostate cancer (GETUG-­?AFU 15): a randomised, pp.open-­?label, 2015.

C. Vale, S. Burdett, L. Rydzewska, L. Albiges, N. Clarke et al., Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, The Lancet Oncology, vol.17, issue.2, pp.243-56, 2016.
DOI : 10.1016/S1470-2045(15)00489-1

M. Kirby, C. Hirst, and E. Crawford, Characterising the castration-resistant prostate cancer population: a systematic review, International Journal of Clinical Practice, vol.13, issue.A615, pp.1180-92, 2011.
DOI : 10.1111/j.1742-1241.2011.02799.x

D. Berthold, G. Pond, F. Soban, R. De-wit, M. Eisenberger et al., Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study, Journal of Clinical Oncology, vol.26, issue.2, pp.242-247, 2008.
DOI : 10.1200/JCO.2007.12.4008

I. Tannock, . De-wit, . Berry, . Horti, and C. Pluzanska, Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. 65 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N Engl J Med, vol.351, issue.15, pp.1513-1533, 2004.
DOI : 10.1056/nejmoa040720

F. Saad, D. Gleason, R. Murray, S. Tchekmedyian, P. Venner et al., Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer, JNCI Journal of the National Cancer Institute, vol.96, issue.11, pp.879-82, 2004.
DOI : 10.1093/jnci/djh141

C. Sternberg, D. Petrylak, O. Sartor, J. Witjes, T. Demkow et al., Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC Trial, Journal of Clinical Oncology, vol.27, issue.32, pp.5431-5439, 2009.
DOI : 10.1200/JCO.2008.20.1228

. Chaumard-­?billotey, Impact of news drugs in the median overall survival of patients with metastatic castration resistant prostate cancer (mCRPC), ASCO Annu Meet, 2013.

N. Mottet, J. Bellmunt, E. Briers, M. Bolla, R. Van-den-bergh et al., EAU guidelines on prostate cancer European Urology Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts, J Urol, vol.71169, issue.5, pp.1729-1763, 2003.

D. Bono and J. , Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-­?resistant prostate cancer progressing after docetaxel treatment: a randomised open-­?label trial, Lancet, 2010.

D. Bono, J. Logothetis, C. Molina, A. , K. Fizazi et al., Abiraterone and Increased Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.364, issue.21, pp.1995-2005, 2011.
DOI : 10.1056/NEJMoa1014618

C. Ryan, M. Smith, K. Fizazi, F. Saad, P. Mulders et al., Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study, The Lancet Oncology, vol.16, issue.2, pp.152-60, 2015.
DOI : 10.1016/S1470-2045(14)71205-7

H. Scher, R. Cabot, N. Harris, E. Rosenberg, J. Shepard et al., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, N Engl J Med, vol.367, issue.13, pp.1187-97, 2012.

T. Beer, A. Armstrong, D. Rathkopf, Y. Loriot, C. Sternberg et al., Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, New England Journal of Medicine, vol.371, issue.5, pp.424-457, 2014.
DOI : 10.1056/NEJMoa1405095

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418931

A. Sartor, S. Oudard, L. Sengeløv, G. Daugaard, F. Saad et al., Cabazitaxel vs docetaxel in chemotherapy-­?naive (CN) patients with metastatic castration-­?resistant prostate cancer (mCRPC): A three-­?arm phase III study (FIRSTANA) Sipuleucel-­?T immunotherapy for castration-­?resistant prostate cancer, J Clin Oncol N Engl J Med, vol.34363, issue.5, pp.2016411-2016433, 2010.

G. Bauman, M. Charette, R. Reid, and J. Sathya, Radiopharmaceuticals for the palliation of painful bone metastasis-­?a systemic review, Radiother Oncol J Eur Soc Ther Radiol Oncol, vol.75, issue.3, pp.258-70, 2005.

C. Parker, S. Nilsson, D. Heinrich, S. Helle, O. Sullivan et al., Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.369, issue.3, pp.213-236, 2013.
DOI : 10.1056/NEJMoa1213755

P. Hoskin, O. Sartor, O. Sullivan, J. Johannessen, D. Helle et al., Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial, The Lancet Oncology, vol.15, issue.12, pp.1397-406, 2014.
DOI : 10.1016/S1470-2045(14)70474-7

N. Houédé, P. Beuzeboc, S. Gourgou, D. Tosi, M. L. Gravis et al., Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use program in France., Journal of Clinical Oncology, vol.33, issue.7_suppl, pp.1471-2407222, 2015.
DOI : 10.1200/jco.2015.33.7_suppl.264

A. Nakouzi, N. , L. Moulec, S. Albigès, L. Wang et al., Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies, European Urology, vol.68, issue.2, pp.228-263, 2015.
DOI : 10.1016/j.eururo.2014.04.015

Y. Loriot, D. Bianchini, E. Ileana, S. Sandhu, A. Patrikidou et al., Antitumour activity of abiraterone acetate against metastatic castration-­?resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Ann Oncol, pp.1807-1819, 2013.

S. Badrising, V. Van-der-noort, I. Van-oort, H. Van-den-berg, M. Los et al., Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment, Cancer, vol.72, issue.15 suppl, pp.968-753391, 2014.
DOI : 10.1002/cncr.28518

M. Smith, D. Bono, J. Sternberg, C. , L. Moulec et al., Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1, Journal of Clinical Oncology, vol.34, issue.25, pp.3005-3018, 2016.
DOI : 10.1200/JCO.2015.65.5597

E. Basch, Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E)., Journal of Clinical Oncology, vol.33, issue.7_suppl, p.2015
DOI : 10.1200/jco.2015.33.7_suppl.141

E. Abstr-141-kwon, C. Drake, H. Scher, K. Fizazi, A. Bossi et al., Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-­?resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-­?043): a multicentre, randomised, double-­?blind, phase 3 trial, Lancet Oncol, vol.8915, issue.7, pp.700-712, 2014.

T. Beer, C. Logothetis, and P. Sharma, CA184-­?095: A randomized, double-­?blind, phase III trial to compare the efficacy of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-­?naive castration-­?resistant prostate cancer (CRPC), J Clin Oncol, vol.30, p.2012

H. Isbarn, L. Boccon-­?gibod, P. Carroll, F. Montorsi, C. Schulman et al., Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks, European Urology, vol.55, issue.1, pp.62-75, 2009.
DOI : 10.1016/j.eururo.2008.10.008

R. Venkitaraman, D. Lorente, V. Murthy, K. Thomas, L. Parker et al., A Randomised Phase 2 Trial of Dexamethasone Versus Prednisolone in Castration-resistant Prostate Cancer, European Urology, vol.67, issue.4, pp.673-682
DOI : 10.1016/j.eururo.2014.10.004

K. Fizazi, M. Carducci, M. Smith, R. Damião, J. Brown et al., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study, The Lancet, vol.377, issue.9768, pp.813-835, 2011.
DOI : 10.1016/S0140-6736(10)62344-6

C. Wang and Y. Shen, Study on the distribution features of bone metastases in prostate cancer, Nuclear Medicine Communications, vol.33, issue.4, pp.379-83
DOI : 10.1097/MNM.0b013e3283504528

R. Coleman, Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity. Clin Cancer Res, pp.6243-6249, 2006.

G. Kiebzak, G. Beinart, K. Perser, C. Ambrose, S. Siff et al., Undertreatment of Osteoporosis in Men With Hip Fracture, Archives of Internal Medicine, vol.162, issue.19, pp.2217-2239, 2002.
DOI : 10.1001/archinte.162.19.2217

A. Feldstein, G. Nichols, E. Orwoll, P. Elmer, D. Smith et al., The near absence of osteoporosis treatment in older men with fractures, Osteoporosis International, vol.161, issue.8, pp.953-62, 2005.
DOI : 10.1007/s00198-005-1950-0

O. Johnell and J. Kanis, An estimate of the worldwide prevalence and disability associated with osteoporotic fractures, Osteoporosis International, vol.16, issue.suppl 2, pp.1726-1759, 2006.
DOI : 10.1007/s00198-006-0172-4

P. Haentjens, J. Magaziner, C. Colón-­?emeric, D. Vanderschueren, K. Milisen et al., Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men, Annals of Internal Medicine, vol.152, issue.6, pp.380-90, 2010.
DOI : 10.7326/0003-4819-152-6-201003160-00008

R. Coleman, Metastatic bone disease: clinical features, pathophysiology and treatment strategies, Cancer Treatment Reviews, vol.27, issue.3, 2001.
DOI : 10.1053/ctrv.2000.0210

J. Bruder, J. Ma, J. Basler, and M. Welch, Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy, Urology, vol.67, issue.1, pp.152-157, 2006.
DOI : 10.1016/j.urology.2005.07.017

V. Shahinian, Y. Kuo, J. Freeman, and J. Goodwin, Risk of Fracture after Androgen Deprivation for Prostate Cancer, New England Journal of Medicine, vol.352, issue.2, pp.154-64, 2005.
DOI : 10.1056/NEJMoa041943

D. Mittan, S. Lee, E. Miller, R. Perez, J. Basler et al., Bone Loss following Hypogonadism in Men with Prostate Cancer Treated with GnRH Analogs, The Journal of Clinical Endocrinology & Metabolism, vol.87, issue.8, pp.3656-61, 2002.
DOI : 10.1210/jcem.87.8.8782

R. Coleman, E. Rathbone, and J. Brown, Management of cancer treatment-induced bone loss, Nature Reviews Rheumatology, vol.22, issue.6, pp.365-74
DOI : 10.1038/nrrheum.2013.36

T. Dorff and E. Crawford, Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer, Annals of Oncology, vol.24, issue.1, pp.31-39, 2013.
DOI : 10.1093/annonc/mds216

P. Ferrari, Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease, Best Practice & Research Clinical Endocrinology & Metabolism, vol.17, issue.4, pp.575-89, 2003.
DOI : 10.1016/S1521-690X(03)00053-8

R. Coleman, J. Body, M. Aapro, P. Hadji, and J. Herrstedt, Bone health in cancer patients: ESMO Clinical Practice Guidelines, Annals of Oncology, vol.25, issue.suppl 3, pp.124-161, 2014.
DOI : 10.1093/annonc/mdu103

S. Greenspan, P. Coates, S. Sereika, J. Nelson, D. Trump et al., Bone Loss after Initiation of Androgen Deprivation Therapy in Patients with Prostate Cancer, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.12, 2005.
DOI : 10.1210/jc.2005-0183

B. Kiratli, S. Srinivas, I. Perkash, and M. Terris, Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer, Urology, vol.57, issue.1, pp.127-159, 2001.
DOI : 10.1016/S0090-4295(00)00895-5

V. Butoescu and B. Tombal, Practical guide to bone health in the spectrum of advanced prostate cancer

M. Smith, Androgen deprivation therapy for prostate cancer: new concepts and concerns, Current Opinion in Endocrinology, Diabetes and Obesity, vol.14, issue.3, pp.247-54, 2007.
DOI : 10.1097/MED.0b013e32814db88c

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047388

S. Alibhai, M. Duong-­?hua, A. Cheung, R. Sutradhar, P. Warde et al., Fracture Types and Risk Factors in Men With Prostate Cancer on Androgen Deprivation Therapy: A Matched Cohort Study of 19,079 Men, The Journal of Urology, vol.184, issue.3, pp.918-941, 2010.
DOI : 10.1016/j.juro.2010.04.068

M. Smith, Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate Cancer, Journal of Clinical Oncology, vol.23, issue.31, pp.7897-903, 2005.
DOI : 10.1200/JCO.2004.00.6908

K. Weinfurt, The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer, Annals of Oncology, vol.16, issue.4, pp.579-84, 2005.
DOI : 10.1093/annonc/mdi122

V. Depuy, K. Anstrom, L. Castel, K. Schulman, K. Weinfurt et al., Effects of skeletal morbidities on longitudinal patient-­?reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer, pp.869-76, 2007.

M. Broder, B. Gutierrez, D. Cherepanov, and Y. Linhares, Burden of skeletal-­?related events in prostate cancer: unmet need in pain improvement. Support Care Cancer, pp.237-284, 2015.

E. Hernlund, A. Svedbom, M. Ivergård, J. Compston, C. Cooper et al., Osteoporosis in the European Union: medical management, epidemiology and economic burden, Archives of Osteoporosis, vol.8, issue.1-2, pp.1-2, 2013.
DOI : 10.1007/s11657-013-0136-1

. Available, 1007/s11657-­?013-­?0136-­?1 Economic Impacts of Skeletal-­?Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone. The Oncologist, pp.320-326, 2016.

K. Fizazi, C. Massard, M. Smith, M. Rader, J. Brown et al., Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer, European Urology, vol.68, issue.1
DOI : 10.1016/j.eururo.2014.10.001

C. Yong, E. Onukwugha, and C. Mullins, Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer, Current Opinion in Oncology, vol.26, issue.3, pp.274-83, 2014.
DOI : 10.1097/CCO.0000000000000071

F. Epstein, S. Manolagas, and R. Jilka, Bone Marrow, Cytokines, and Bone Remodeling ??? Emerging Insights into the Pathophysiology of Osteoporosis, New England Journal of Medicine, vol.332, issue.5, pp.305-316, 1995.
DOI : 10.1056/NEJM199502023320506

E. Seeman and P. Delmas, Bone Quality ??? The Material and Structural Basis of Bone Strength and Fragility, New England Journal of Medicine, vol.354, issue.21, pp.2250-61, 2006.
DOI : 10.1056/NEJMra053077

D. Lacey, E. Timms, H. Tan, M. Kelley, C. Dunstan et al., Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation, Cell, vol.93, issue.2, pp.165-76, 1998.
DOI : 10.1016/S0092-8674(00)81569-X

URL : http://doi.org/10.1016/s0092-8674(00)81569-x

H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki et al., Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL, Proceedings of the National Academy of Sciences, vol.95, issue.7, pp.3597-602, 1998.
DOI : 10.1073/pnas.95.7.3597

Y. Kong, H. Yoshida, I. Sarosi, H. Tan, E. Timms et al., OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-­?node organogenesis, Nature, vol.397, issue.6717, pp.315-338, 1999.

W. Simonet, D. Lacey, C. Dunstan, M. Kelley, M. Chang et al., Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, vol.89, issue.2, pp.309-328, 1997.
DOI : 10.1016/S0092-8674(00)80209-3

H. Yasuda, N. Shima, N. Nakagawa, S. Mochizuki, K. Yano et al., Identity of Osteoclastogenesis Inhibitory Factor (OCIF) and Osteoprotegerin (OPG): A Mechanism by which OPG/OCIF Inhibits Osteoclastogenesis in Vitro, Endocrinology, vol.139, issue.3, pp.1329-1366, 1998.
DOI : 10.1210/en.139.3.1329

C. Confavreux, R. Levine, and G. Karsenty, A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms, Molecular and Cellular Endocrinology, vol.310, issue.1-2, pp.1-221, 2009.
DOI : 10.1016/j.mce.2009.04.004

URL : https://hal.archives-ouvertes.fr/hal-00512215

E. Keller and J. Brown, Prostate cancer bone metastases promote both osteolytic and osteoblastic activity, Journal of Cellular Biochemistry, vol.86, issue.1
DOI : 10.1002/jcb.10662

B. Gartrell and F. Saad, Managing bone metastases and reducing skeletal related events in prostate cancer, Nature Reviews Clinical Oncology, vol.65, issue.6, pp.335-380, 2014.
DOI : 10.1002/jbmr.1613

J. Currey, The effect of porosity and mineral content on the Young's modulus of elasticity of compact bone, Journal of Biomechanics, vol.21, issue.2, pp.131-140, 1988.
DOI : 10.1016/0021-9290(88)90006-1

D. Cooper, C. Thomas, J. Clement, A. Turinsky, C. Sensen et al., Age-dependent change in the 3D structure of cortical porosity at the human femoral midshaft, Bone, vol.40, issue.4, pp.957-65, 2007.
DOI : 10.1016/j.bone.2006.11.011

A. Falahati-­?nini, B. Riggs, E. Atkinson, O. Fallon, W. Eastell et al., Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men, Journal of Clinical Investigation, vol.106, issue.12, pp.1553-60, 2000.
DOI : 10.1172/JCI10942

B. Leder, K. Leblanc, D. Schoenfeld, R. Eastell, and J. Finkelstein, Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.1, pp.204-214, 2003.
DOI : 10.1210/jc.2002-021036

S. Epstein, G. Bryce, J. Hinman, O. Miller, B. Riggs et al., The influence of age on bone mineral regulating hormones, Bone, vol.7, issue.6, pp.421-426, 1986.
DOI : 10.1016/8756-3282(86)90001-3

J. Pfeilschifter, C. Scheidt-­?nave, G. Leidig-­?bruckner, H. Woitge, W. Blum et al., Relationship between circulating insulin-­?like growth factor components and sex hormones in a population-­?based sample of 50-­? to 80-­?year-­?old men and women, J Clin Endocrinol Metab, vol.81, issue.7, pp.2534-2574, 1996.

P. Szulc, J. ?. Pharaboz, M. Marchand, F. Delmas, and P. , Insulin-Like Growth Factor I Is a Determinant of Hip Bone Mineral Density in Men Less Than 60 years of Age: MINOS Study, Calcified Tissue International, vol.76, issue.4, 2004.
DOI : 10.1007/s00223-003-0090-9

J. Walsh and R. Eastell, Osteoporosis in men, Nature Reviews Endocrinology, vol.21, issue.11, pp.637-682, 2013.
DOI : 10.1038/nrendo.2013.171

J. Rey, E. Cervino, M. Rentero, E. Crespo, A. Álvaro et al., Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice Available from, Open Orthop J, vol.3, issue.1, 2009.

A. Roelofs, K. Thompson, F. Ebetino, M. Rogers, and F. Coxon, Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages, Current Pharmaceutical Design, vol.16, issue.27, pp.2950-60, 2010.
DOI : 10.2174/138161210793563635

P. Meunier, M. Arlot, P. Chavassieux, and A. Yates, The effects of alendronate on bone turnover and bone quality, Int J Clin Pract, vol.101, pp.14-21, 1999.

J. Brown and R. Coleman, Denosumab in patients with cancer???a surgical strike against the osteoclast, Nature Reviews Clinical Oncology, vol.11, issue.2
DOI : 10.1038/nrclinonc.2011.197

P. Bekker, D. Holloway, A. Rasmussen, R. Murphy, S. Martin et al., A Single-Dose Placebo-Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women, Journal of Bone and Mineral Research, vol.273, issue.7, pp.1059-66, 2004.
DOI : 10.1359/JBMR.040305

K. Fizazi, A. Lipton, X. Mariette, J. Body, Y. Rahim et al., Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates, Journal of Clinical Oncology, vol.27, issue.10, pp.1564-71, 2009.
DOI : 10.1200/JCO.2008.19.2146

A. Gangi, T. Sabharwal, F. Irani, X. Buy, J. Morales et al., Quality Assurance Guidelines for Percutaneous Vertebroplasty, CardioVascular and Interventional Radiology, vol.18, issue.1, pp.173-181, 2006.
DOI : 10.1007/s00270-005-0146-5

H. Fink, D. Milavetz, L. Palermo, M. Nevitt, J. Cauley et al., What Proportion of Incident Radiographic Vertebral Deformities Is Clinically Diagnosed and Vice Versa? J Bone Miner Res, pp.1216-1238, 2005.

T. Van-geel, K. Huntjens, J. Van-den-bergh, G. Dinant, and P. Geusens, Timing of Subsequent Fractures after an Initial Fracture, Current Osteoporosis Reports, vol.92, issue.3, pp.118-140, 2010.
DOI : 10.1007/s11914-010-0023-2

O. Johnell, J. Kanis, A. Odén, I. Sernbo, I. Petterson et al., Fracture risk following an osteoporotic fracture, Osteoporosis International, vol.15, issue.3, pp.175-184, 2004.
DOI : 10.1007/s00198-003-1514-0

P. Klimo and M. Schmidt, Surgical Management of Spinal Metastases, The Oncologist, vol.9, issue.2, pp.188-96, 2004.
DOI : 10.1634/theoncologist.9-2-188

T. Bartalena, G. Giannelli, M. Rinaldi, E. Rimondi, G. Rinaldi et al., Prevalence of thoracolumbar vertebral fractures on multidetector CT, European Journal of Radiology, vol.69, issue.3, 2009.
DOI : 10.1016/j.ejrad.2007.11.036

A. Williams, A. Sparrow, P. Adams, J. Whitehouse, and R. , Under-reporting of osteoporotic vertebral fractures on computed tomography, European Journal of Radiology, vol.69, issue.1, pp.179-83, 2009.
DOI : 10.1016/j.ejrad.2007.08.028

H. Genant, C. Wu, C. Van-kuijk, and M. Nevitt, Vertebral fracture assessment using a semiquantitative technique, Journal of Bone and Mineral Research, vol.13, issue.S1, pp.1137-1185, 1993.
DOI : 10.1002/jbmr.5650080915

J. Laredo, G. Abi-­?ayad-a-morvan, J. Laredo, and M. Wybier, Diagnostic d'un tassement vertébral non traumatique récent, Imagerie ostéo-­?articulaire, pp.1293-310, 1998.

J. Laredo, K. Lakhdari, L. Bellaïche, B. Hamze, P. Janklewicz et al., Acute vertebral collapse: CT findings in benign and malignant nontraumatic cases., Radiology, vol.194, issue.1, pp.41-49, 1995.
DOI : 10.1148/radiology.194.1.7997579

S. Hwang and D. Panicek, Magnetic resonance imaging of bone marrow in oncology, Part 2. Skeletal Radiol, pp.1017-1044, 2007.

C. Hanrahan and L. Shah, MRI of Spinal Bone Marrow: Part 2, T1-Weighted Imaging-Based Differential Diagnosis, American Journal of Roentgenology, vol.197, issue.6, pp.1309-1330, 2011.
DOI : 10.2214/AJR.11.7420

C. Cuénod, J. Laredo, S. Chevret, B. Hamze, J. Naouri et al., Acute vertebral collapse due to osteoporosis or malignancy: appearance on unenhanced and gadolinium-enhanced MR images., Radiology, vol.199, issue.2, pp.541-550, 1996.
DOI : 10.1148/radiology.199.2.8668809

W. Yuh, C. Zachar, T. Barloon, Y. Sato, W. Sickels et al., Vertebral compression fractures: distinction between benign and malignant causes with MR imaging., Radiology, vol.172, issue.1, pp.215-223, 1989.
DOI : 10.1148/radiology.172.1.2740506

A. Baur, A. Stäbler, R. Brüning, R. Bartl, A. Krödel et al., Diffusion-weighted MR imaging of bone marrow: differentiation of benign versus pathologic compression fractures., Radiology, vol.207, issue.2, pp.349-56, 1998.
DOI : 10.1148/radiology.207.2.9577479

W. Erly, E. Oh, and E. Outwater, The utility of in-­?phase/opposed-­?phase imaging in differentiating malignancy from acute benign compression fractures of the spine, Am J Neuroradiol, vol.27, issue.6, pp.1183-1191, 2006.

S. Pneumaticos, S. Chatziioannou, C. Savvidou, A. Pilichou, D. Rontogianni et al., Routine needle biopsy during vertebral augmentation procedures. Is it necessary? Eur Spine J, pp.1894-1902, 2010.
DOI : 10.1007/s00586-010-1388-8

C. Torres and I. Hammond, Computed Tomography and Magnetic Resonance Imaging in the Differentiation of Osteoporotic Fractures From Neoplastic Metastatic Fractures, Journal of Clinical Densitometry, vol.19, issue.1, 2015.
DOI : 10.1016/j.jocd.2015.08.008

J. Kanis, H. Johansson, A. Oden, O. Johnell, D. Laet et al., A family history of fracture and fracture risk: a meta-analysis, Bone, vol.35, issue.5, pp.1029-1066, 2004.
DOI : 10.1016/j.bone.2004.06.017

J. Kanis, O. Johnell, D. Laet, C. Johansson, H. Oden et al., A meta-analysis of previous fracture and subsequent fracture risk, Bone, vol.35, issue.2, pp.375-82, 2004.
DOI : 10.1016/j.bone.2004.03.024

D. Laet, C. Kanis, J. Odén, A. Johanson, H. Johnell et al., Body mass index as a predictor of fracture risk: A meta-analysis, Osteoporosis International, vol.14, issue.11, pp.1330-1338, 2005.
DOI : 10.1007/s00198-005-1863-y

J. Kanis, O. Johnell, A. Oden, H. Johansson, D. Laet et al., Smoking and fracture risk: a meta-analysis, Osteoporosis International, vol.15, issue.2, pp.155-62, 2005.
DOI : 10.1007/s00198-004-1640-3

J. Kanis, H. Johansson, O. Johnell, A. Oden, D. Laet et al., Alcohol intake as a risk factor for fracture, Osteoporosis International, vol.13, issue.7, pp.737-779, 2005.
DOI : 10.1007/s00198-004-1734-y

C. Bellera, M. Rainfray, S. Mathoulin-­?pelissier, C. Mertens, F. Delva et al., Screening older cancer patients: first evaluation of the G-8 geriatric screening tool, Annals of Oncology, vol.23, issue.8, pp.2166-72, 2012.
DOI : 10.1093/annonc/mdr587

P. Soubeyran, M. Fonck, C. Blanc-­?bisson, J. Blanc, J. Ceccaldi et al., Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer, Journal of Clinical Oncology, vol.30, issue.15, pp.1829-1863, 2012.
DOI : 10.1200/JCO.2011.35.7442

D. Marshall, O. Johnell, and H. Wedel, Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, BMJ, vol.312, issue.7041, pp.1254-1263, 1996.
DOI : 10.1136/bmj.312.7041.1254

E. Siris, P. Miller, E. Barrett-­?connor, K. Faulkner, L. Wehren et al., Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women, JAMA, vol.286, issue.22, pp.2815-2837, 2001.
DOI : 10.1001/jama.286.22.2815

S. Schuit, M. Van-der-klift, A. Weel, C. De-laet, H. Burger et al., Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study, Bone, vol.34, issue.1, 2004.
DOI : 10.1016/j.bone.2003.10.001

A. Heidenreich, P. Bastian, J. Bellmunt, M. Bolla, S. Joniau et al., EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer, European Urology, vol.65, issue.2, pp.467-79, 2014.
DOI : 10.1016/j.eururo.2013.11.002

J. Kanis, O. Johnell, A. Oden, H. Johansson, and E. Mccloskey, FRAX TM and the assessment of fracture probability in men and women from the UK. Osteoporos Int, pp.385-97, 2008.

A. Tosteson, L. Melton, B. Dawson-­?hughes, S. Baim, M. Favus et al., Cost-effective osteoporosis treatment thresholds: the United States perspective, Osteoporosis International, vol.15, issue.4, pp.437-484, 2008.
DOI : 10.1007/s00198-007-0550-6

J. Kanis, E. Mccloskey, H. Johansson, O. Strom, F. Borgstrom et al., Case finding for the management of osteoporosis with FRAX®?assessment and intervention thresholds for the UK. Osteoporos Int, pp.1395-408, 2008.

C. Roux and T. Thomas, Du bon usage du FRAX??, Revue du Rhumatisme, vol.76, issue.1, pp.1-3, 2009.
DOI : 10.1016/j.rhum.2008.11.001

P. Saylor, D. Kaufman, M. Michaelson, R. Lee, and M. Smith, Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer, The Journal of Urology, vol.183, issue.6, pp.2200-2205, 2010.
DOI : 10.1016/j.juro.2010.02.022

H. James, I. Aleksic, M. Bienz, C. Pieczonka, P. Iannotta et al., Comparison of Fracture Risk Assessment Tool Score to Bone Mineral Density for Estimating Fracture Risk in Patients With Advanced Prostate Cancer on Androgen Deprivation Therapy, Urology, vol.84, issue.1, pp.164-172, 2014.
DOI : 10.1016/j.urology.2013.12.071

R. Adler, Management of osteoporosis in men on androgen deprivation therapy, Maturitas, vol.68, issue.2, 2011.
DOI : 10.1016/j.maturitas.2010.11.003

J. Planas, J. Morote, A. Orsola, C. Salvador, E. Trilla et al., The relationship between daily calcium intake and bone mineral density in men with prostate cancer, BJU International, vol.173, issue.4, pp.812-818, 2007.
DOI : 10.1111/j.1464-410X.2006.05885.x

H. Bischoff-­?ferrari, W. Willett, E. Orav, P. Lips, P. Meunier et al., A Pooled Analysis of Vitamin D Dose Requirements for Fracture Prevention, New England Journal of Medicine, vol.367, issue.1, pp.40-49, 2012.
DOI : 10.1056/NEJMoa1109617

B. Tang, G. Eslick, C. Nowson, C. Smith, and A. Bensoussan, Use of Calcium or Calcium in Combination With Vitamin D Supplementation to Prevent Fractures and Bone Loss in People Aged 50 Years and Older: A Meta-analysis, Obstetrical & Gynecological Survey, vol.63, issue.1, pp.657-66, 2007.
DOI : 10.1097/01.ogx.0000298339.68546.3c

I. Reid, M. Bolland, P. Sambrook, and A. Grey, Calcium supplementation: Balancing the cardiovascular risks, Maturitas, vol.69, issue.4, pp.289-95, 2011.
DOI : 10.1016/j.maturitas.2011.04.014

M. Datta and G. Schwartz, Calcium and Vitamin D Supplementation During Androgen Deprivation Therapy for Prostate Cancer: A Critical Review, The Oncologist, vol.17, issue.9, pp.1171-1180, 2012.
DOI : 10.1634/theoncologist.2012-0051

M. Smith, S. Malkowicz, F. Chu, J. Forrest, D. Price et al., Toremifene Increases Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer: Interim Analysis of a Multicenter Phase 3 Clinical Study, The Journal of Urology, vol.179, issue.1, pp.152-157, 2008.
DOI : 10.1016/j.juro.2007.08.137

M. Smith, M. Fallon, H. Lee, and J. Finkelstein, Raloxifene to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men with Prostate Cancer: A Randomized Controlled Trial, The Journal of Clinical Endocrinology & Metabolism, vol.89, issue.8, pp.3841-3847, 2004.
DOI : 10.1210/jc.2003-032058

M. Smith, R. Morton, K. Barnette, P. Sieber, S. Malkowicz et al., Toremifene to Reduce Fracture Risk in Men Receiving Androgen Deprivation Therapy for Prostate Cancer, J Urol, 2010.

M. Smith, S. Malkowicz, M. Brawer, M. Hancock, R. Morton et al., Toremifene Decreases Vertebral Fractures in Men Younger Than 80 Years Receiving Androgen Deprivation Therapy for Prostate Cancer, The Journal of Urology, vol.186, issue.6, pp.2239-2283, 2011.
DOI : 10.1016/j.juro.2011.07.090

S. Greenspan, J. Nelson, D. Trump, J. Wagner, M. Miller et al., Skeletal Health After Continuation, Withdrawal, or Delay of Alendronate in Men With Prostate Cancer Undergoing Androgen-Deprivation Therapy, Journal of Clinical Oncology, vol.26, issue.27, pp.4426-4460, 2008.
DOI : 10.1200/JCO.2007.15.1233

M. Smith, F. Mcgovern, A. Zietman, M. Fallon, D. Hayden et al., Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer, New England Journal of Medicine, vol.345, issue.13, pp.948-55, 2001.
DOI : 10.1056/NEJMoa010845

T. Diamond, J. Winters, A. Smith, D. Souza, P. Kersley et al., The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade, Cancer, vol.88, issue.6, pp.1444-50, 2001.
DOI : 10.1002/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M

N. Morabito, A. Gaudio, A. Lasco, A. Catalano, M. Atteritano et al., Neridronate Prevents Bone Loss in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer, Journal of Bone and Mineral Research, vol.69, issue.11, pp.1766-70, 2004.
DOI : 10.1359/JBMR.040813

M. Smith, J. Eastham, D. Gleason, D. Shasha, S. Tchekmedyian et al., Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer, The Journal of Urology, vol.169, issue.6, pp.2008-2020, 2003.
DOI : 10.1097/01.ju.0000063820.94994.95

M. Michaelson, D. Kaufman, H. Lee, F. Mcgovern, P. Kantoff et al., Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist???Induced Bone Loss in Men With Prostate Cancer, Journal of Clinical Oncology, vol.25, issue.9, pp.1038-1080, 2007.
DOI : 10.1200/JCO.2006.07.3361

C. Ryan, D. Huo, L. Demers, T. Beer, and L. Lacerna, Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer, The Journal of Urology, vol.176, issue.3, 2006.
DOI : 10.1016/j.juro.2006.04.078

M. Smith, B. Egerdie, N. Toriz, R. Feldman, T. Tammela et al., Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer, New England Journal of Medicine, vol.361, issue.8, pp.745-55, 2009.
DOI : 10.1056/NEJMoa0809003

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3038121

P. Hadji, J. Body, M. Aapro, A. Brufsky, R. Coleman et al., Practical guidance for the management of aromatase inhibitor-associated bone loss, Annals of Oncology, vol.19, issue.8, pp.1407-1423, 2008.
DOI : 10.1093/annonc/mdn164

M. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi et al., Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial, The Lancet, vol.379, issue.9810, pp.39-46, 2012.
DOI : 10.1016/S0140-6736(11)61226-9

D. Dearnaley and . Double-­?blind, Placebo-­?Controlled, Randomized Trial of Oral Sodium Clodronate for Metastatic Prostate Cancer (MRC PR05 Trial). CancerSpectrum Knowl Environ, pp.1300-1311, 2003.

D. Dearnaley, M. Mason, M. Parmar, K. Sanders, and M. Sydes, Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials, The Lancet Oncology, vol.10, issue.9, pp.872-878, 2009.
DOI : 10.1016/S1470-2045(09)70201-3

M. Smith, S. Halabi, C. Ryan, A. Hussain, N. Vogelzang et al., Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance), Journal of Clinical Oncology, vol.32, issue.11, pp.1143-50, 2014.
DOI : 10.1200/JCO.2013.51.6500

P. Saylor, Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer, Asian Journal of Andrology, vol.16, issue.3, p.341, 2014.
DOI : 10.4103/1008-682X.122591

M. Smith, R. Coleman, L. Klotz, K. Pittman, P. Milecki et al., Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events, Annals of Oncology, vol.26, issue.2, pp.368-74
DOI : 10.1093/annonc/mdu519

D. Henry, L. Costa, F. Goldwasser, V. Hirsh, V. Hungria et al., Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma, Journal of Clinical Oncology, vol.29, issue.9, pp.1125-1157, 2011.
DOI : 10.1200/JCO.2010.31.3304

C. Logothetis, E. Basch, A. Molina, K. Fizazi, S. North et al., Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial, The Lancet Oncology, vol.13, issue.12, pp.1210-1217, 2012.
DOI : 10.1016/S1470-2045(12)70473-4

K. Fizazi, H. Scher, K. Miller, E. Basch, C. Sternberg et al., Effect of enzalutamide on time to first skeletal-­?related event, pain, and quality of life in men with castration-­?resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial health-­?related quality of life, pain, and skeletal-­?related events in asymptomatic and minimally symptomatic, chemotherapy-­?naive patients with metastatic castration-­?resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial, Lancet Oncol. Lancet Oncol, vol.1516, issue.105, pp.1147-56509, 2014.

H. Balkarli, H. Demirtas, M. Kilic, and I. Ozturk, Treatment of osteoporotic vertebral compression fractures with percutaneous vertebroplasty under local anesthesia: clinical and radiological results, Int J Clin Exp Med, vol.8, issue.9, p.16287, 2015.

P. Galibert, H. Deramond, P. Rosat, L. Gars, and D. , Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty], Neurochirurgie, vol.33, issue.2, pp.166-174, 1987.

J. Mcgraw, J. Lippert, K. Minkus, P. Rami, T. Davis et al., Prospective Evaluation of Pain Relief in 100 Patients Undergoing Percutaneous Vertebroplasty: Results and Follow-up, Journal of Vascular and Interventional Radiology, vol.13, issue.9, 2002.
DOI : 10.1016/S1051-0443(07)61770-9

G. Zoarski, P. Snow, W. Olan, M. Stallmeyer, B. Dick et al., Percutaneous Vertebroplasty for Osteoporotic Compression Fractures: Quantitative Prospective Evaluation of Long-term Outcomes, Journal of Vascular and Interventional Radiology, vol.13, issue.2, pp.139-187, 2002.
DOI : 10.1016/S1051-0443(07)61930-7

J. Mathis and W. Wong, Percutaneous Vertebroplasty: Technical Considerations, Journal of Vascular and Interventional Radiology, vol.14, issue.8, pp.953-60, 2003.
DOI : 10.1097/01.RVI.0000083255.29749.A8

J. Palussière, F. Dixmerias, X. Buy, E. Descat, F. Bonichon et al., Traitement des métastases osseuses par radiologie interventionnelle, Bull Cancer (Paris), vol.96, issue.11, pp.1117-1143, 2009.

J. Tian, L. Xiang, D. Zhou, Q. Fan, and B. Ma, The clinical efficacy of vertebroplasty on osteoporotic vertebral compression fracture: A meta-analysis, International Journal of Surgery, vol.12, issue.12, pp.1249-53, 2014.
DOI : 10.1016/j.ijsu.2014.10.027

D. Kallmes, B. Comstock, P. Heagerty, J. Turner, D. Wilson et al., A Randomized Trial of Vertebroplasty for Osteoporotic Spinal Fractures, New England Journal of Medicine, vol.361, issue.6, pp.569-79, 2009.
DOI : 10.1056/NEJMoa0900563

R. Buchbinder, R. Osborne, P. Ebeling, J. Wark, P. Mitchell et al., A Randomized Trial of Vertebroplasty for Painful Osteoporotic Vertebral Fractures, New England Journal of Medicine, vol.361, issue.6, pp.557-68, 2009.
DOI : 10.1056/NEJMoa0900429

A. Gangi and W. Clark, Have Recent Vertebroplasty Trials Changed the Indications for Vertebroplasty? Cardiovasc Intervent Radiol, pp.677-80, 2010.
DOI : 10.1007/s00270-010-9901-3

J. Laredo and B. Hamze, Complications of percutaneous vertebroplasty and their prevention Available from, Skeletal Radiol [Internet], vol.33, issue.9, pp.256-260, 2004.

F. Monticelli, H. Meyer, and E. Tutsch-­?bauer, Fatal pulmonary cement embolism following percutaneous vertebroplasty (PVP) Forensic Sci Int, pp.35-43, 2005.
DOI : 10.1016/j.forsciint.2004.06.010

Y. Zhang, L. Kong, J. Cao, W. Ding, and Y. Shen, Incidence of subsequent vertebral body fractures after vertebroplasty, Journal of Clinical Neuroscience, vol.21, issue.8, pp.1292-1299, 2014.
DOI : 10.1016/j.jocn.2013.12.022

T. Mccall, C. Cole, and A. Dailey, Vertebroplasty and kyphoplasty: a comparative review of efficacy and adverse events, Current Reviews in Musculoskeletal Medicine, vol.18, issue.Suppl 2, pp.17-23, 2008.
DOI : 10.1007/s12178-007-9013-0

R. Cathomas, Z. Bajory, M. Bouzid, E. Ghoneimy, A. Gillessen et al., Management of Bone Metastases in Patients with Castration-Resistant Prostate Cancer, Urologia Internationalis, vol.92, issue.4, pp.377-86, 2014.
DOI : 10.1159/000358258

N. Eastley, M. Newey, and R. Ashford, Skeletal metastases ??? The role of the orthopaedic and spinal surgeon, Surgical Oncology, vol.21, issue.3, pp.216-238, 2012.
DOI : 10.1016/j.suronc.2012.04.001

T. Sande, R. Ruenes, J. Lund, O. Bruland, K. Hornslien et al., Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: Results from a randomised multicentre trial, Radiotherapy and Oncology, vol.91, issue.2, pp.261-267, 2009.
DOI : 10.1016/j.radonc.2009.02.014

W. Hartsell, C. Scott, D. Bruner, C. Scarantino, R. Ivker et al., Randomized Trial of Short- Versus Long-Course Radiotherapy for Palliation of Painful Bone Metastases, JNCI Journal of the National Cancer Institute, vol.97, issue.11, pp.798-804, 2005.
DOI : 10.1093/jnci/dji139

F. Arnalot, P. Fontanals, A. Galcerán, J. Lynd, F. Latiesas et al., Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30Gy in 10 fractions compared with 8Gy in single fraction, Radiotherapy and Oncology, vol.89, issue.2, pp.150-155, 2008.
DOI : 10.1016/j.radonc.2008.05.018

A. Weill, J. Chiras, J. Simon, M. Rose, T. Sola-­?martinez et al., Spinal metastases: indications for and results of percutaneous injection of acrylic surgical cement., Radiology, vol.199, issue.1, pp.241-248, 1996.
DOI : 10.1148/radiology.199.1.8633152

P. Kaemmerlen, P. Thiesse, J. P. Bérard, C. Duquesnel, J. Bascoulergue et al., Percutaneous injection of orthopedic cement in metastatic vertebral lesions, N Engl J Med Jul, vol.13321, issue.2, p.121, 1989.

L. Alvarez, A. Pérez-­?higueras, D. Quiones, E. Calvo, and R. Rossi, Vertebroplasty in the treatment of vertebral tumors: postprocedural outcome and quality of life, European Spine Journal, vol.12, issue.4, pp.356-60, 2003.
DOI : 10.1007/s00586-003-0525-z

A. Wu and D. Fourney, Supportive care aspects of vertebroplasty in patients with cancer. Support Cancer Ther, pp.98-104, 2005.

Y. Tseng, Y. Lo, L. Chen, P. Lai, and S. Yang, Percutaneous polymethylmethacrylate vertebroplasty in the treatment of pain induced by metastatic spine tumor, Surgical Neurology, vol.70, issue.1, pp.178-83, 2008.
DOI : 10.1016/j.surneu.2008.08.078

C. Trumm, T. Jakobs, C. Zech, T. Helmberger, M. Reiser et al., CT Fluoroscopy???guided Percutaneous Vertebroplasty for the Treatment of Osteolytic Breast Cancer Metastases: Results in 62 Sessions with 86 Vertebrae Treated, Journal of Vascular and Interventional Radiology, vol.19, issue.11, pp.1596-606, 2008.
DOI : 10.1016/j.jvir.2008.08.014

N. Aebli, B. Goss, P. Thorpe, R. Williams, and J. Krebs, In Vivo Temperature Profile of Intervertebral Discs and Vertebral Endplates During Vertebroplasty, Spine, vol.31, issue.15, pp.1674-1682, 2006.
DOI : 10.1097/01.brs.0000224193.52587.d8

V. Calmels, J. Vallee, M. Rose, and J. Chiras, Osteoblastic and mixed spinal metastases: evaluation of the analgesic efficacy of percutaneous vertebroplasty, Am J Neuroradiol, vol.28, issue.3, pp.570-574, 2007.

P. Tai, A. Hammond, J. Dyk, L. Stitt, T. J. Coad et al., Pelvic fractures following irradiation of endometrial and vaginal cancers???a case series and review of literature, Radiotherapy and Oncology, vol.56, issue.1, pp.23-31, 2000.
DOI : 10.1016/S0167-8140(00)00178-X

S. I?dem, G. Alço, T. Ercan, M. Barlan, K. Ganiyusufo?lu et al., Insufficiency Fractures After Pelvic Radiotherapy in Patients With Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics, vol.77, issue.3, pp.818-841, 2010.
DOI : 10.1016/j.ijrobp.2009.05.059

E. Yu, K. Kuo, R. Gulati, S. Chen, T. Gambol et al., Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer, Journal of Clinical Oncology, vol.30, issue.15, pp.1864-70, 2012.
DOI : 10.1200/JCO.2011.38.3745

K. Fizazi, K. Chi, J. De-bono, L. Gomella, K. Miller et al., Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer, European Urology, vol.70, issue.3, 2016.
DOI : 10.1016/j.eururo.2016.02.035

R. Govindarajan, M. Khan, S. Gujja, and A. Holt, Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy, Cancer Management and Research, 2014.
DOI : 10.2147/CMAR.S74116

H. Beltran, S. Tomlins, A. Aparicio, V. Arora, D. Rickman et al., Aggressive Variants of Castration-­? Resistant Prostate Cancer. Clin Cancer Res, pp.2846-50, 2014.

J. Reddington, G. Mendez, A. Ching, C. Kubicky, P. Klimo et al., Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic, Surg Neurol Int, vol.7, pp.361-366, 2016.

G. Mundy, Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities, Nature Reviews Cancer, vol.2, issue.8, pp.584-93, 2002.
DOI : 10.1038/nrc867

A. Aparicio, A. Harzstark, P. Corn, S. Wen, J. Araujo et al., Platinum-­?Based Chemotherapy for Variant Castrate-­?Resistant Prostate Cancer. Clin Cancer Res, pp.3621-3651, 2013.
DOI : 10.1158/1078-0432.ccr-12-3791

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699964